|Awarded On||August 20, 2014|
|Title||Novel Small Molecule Probes Targeting IDH Mutated Glioma|
|Award Mechanism||Individual Investigator|
|Institution/Organization||Baylor College of Medicine|
|Principal Investigator/Program Director||Yongcheng Song|
|Cancer Sites||Brain and Other Nervous System|
Glioma is the most common form of brain tumors and can be classified into four grades at diagnosis. Grade I is a type of benign tumor. However, grades II and III gliomas are invasive, which can often progress to highly malignant, grade IV disease, i.e., secondary glioblastoma multiforme (GBM). Secondary GBM is a lethal disease with a median survival of 3.8 year as well as less than 10% 5-year survival rate for the patients. There is therefore a pressing need to find new therapeutics to treat gliomas. Isocitrate dehydrogenase (IDH) is one of the key enzymes in human metabolism. DNA sequencing of more than 1,000 human giloma samples has revealed that 75% of low-medium grade gliomas and seconda...